Preliminary findings indicate that TB-500 might enhance not only the viability, angiogenesis, and migration of HUVEC but could also elevate the expression of angiopoietin-2 (Ang2), TEK receptor tyrosine kinase 2 (tie2), vascular endothelial growth factor A (VEGFA), NOTCH1 intracellular domain (N1ICD), Notch receptor 3 (Notch3), NF-B, and phosphorylated (p)-p65 in these cells
Research use only For qualified researchers
While at the University of Maryland, she received a small grant from Merck, and in collaboration with Karl Folkers from that company, developed the LLD assay
Online access does not prove safety or legitimacy
To learn more about the benefits, risks, & differences of compounded medication substitutes you may visit the FDA Drug Shortage List & FDA Compounding Substitutions Information Page
Ultimately, the integrity of your research hinges on controlling variables